International investment bank Jefferies has significantly raised its price target for Dutch health technology giant Philips, citing a critical structural turning point in the company's vital Diagnosis and Treatment division. Analysts note that heavily rebuilt order books are finally converting into strong revenue growth across Asia-Pacific and Latin America, mitigating ongoing regulatory uncertainties.